Verapamil for Neuroprotection in Stroke

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Global Neurosciences Institute
• Treatments: Verapamil

Criteria

Inclusion Criteria:

• Written informed consent

• 18 years of age and over

• Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia

• Candidate for mechanical thrombectomy procedure

• Onset of symptoms less than 8 hours

• Measurable neurologic deficit (NIHSS >1)

• Willingness to follow up with rehabilitation therapy

• Anticipated life expectancy of at least 3 months

Exclusion Criteria:

• Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)

• Hepatic and/or renal insufficiency (LFT's>3× upper limit of normal; CrCl < 30ml/min)

• Thrombocytopenia (platelet count <75,000/mm3)

• History of intolerance to verapamil

• Previous functional disability (modified Rankin > 1)

• Stuporous or comatose

• Unlikely to be available for 90 day follow-up

• Severe stroke (NIHSS>22)